"Strahm, B." . "RIV/00064203:_____/11:7013" . . . . "Star\u00FD, Jan" . . "2"^^ . . . "Sedl\u00E1\u010Dek, Petr" . . "myelodysplastic syndrome; stem cell transplantation; children; acute myeloid-leukemia; juvenile myelomonocytic leukemia; bone-marrow-transplantation; versus-host-disease; childhood; graft; classification; experience; survival; therapy"@en . . . "Trebo, M." . "Locatelli, F." . "O\\'Marcaigh, A." . "25" . "Nollke, P." . "Leukemia" . "8"^^ . . "van den Heuvel-Eibrink, MM" . "Wojcik, D." . . "de Heredia, CD" . "Bierings, M." . "Moerloose, BD" . "http://www.ncbi.nlm.nih.gov/pubmed/21212791" . "Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study" . "I" . "21"^^ . "RIV/00064203:_____/11:7013!RIV12-MZ0-00064203" . "201874" . . . "Schmugge, M." . "Bordon, V." . . "0887-6924" . "Zecca, M." . . . "Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study"@en . "000288159500008" . . . . "We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n = 53), RAEB in transformation (RAEB-T, n = 29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n = 15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n = 57) or alternative family donor (n = 1). Stem cell source was bone marrow (n = 69) or peripheral blood (n = 28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS. Leukemia (2011) 25, 455-462; doi:10.1038/leu.2010.297; published online 7 January 2011" . "3" . "Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study"@en . . "[7A129A2A4824]" . . "Niemeyer, CM" . "Bergstraesser, E." . . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . . "We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n = 53), RAEB in transformation (RAEB-T, n = 29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n = 15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n = 57) or alternative family donor (n = 1). Stem cell source was bone marrow (n = 69) or peripheral blood (n = 28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS. Leukemia (2011) 25, 455-462; doi:10.1038/leu.2010.297; published online 7 January 2011"@en . . . "Chybicka, A." . . "Furlan, I." . "Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study" . "Peters, C." . "Korthof, ET" .